MetLife, Inc. logo MET - MetLife, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 26
HOLD 7
SELL 0
STRONG
SELL
0
| PRICE TARGET: $108.25 DETAILS
HIGH: $111.00
LOW: $103.00
MEDIAN: $109.50
CONSENSUS: $108.25
UPSIDE: 8.21%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Banks, Insurers & Asset Managers 85% confidence

Primary model: P/Tangible Book × ROE Quality

Valuation Signal Overvalued Mild
Trading 12.3% above fair value
Current Price $100.04
Bear Case $62.37 37.7% downside ($62.37 - $100.04) / $100.04 = -37.7% ROTCE 8.9% → 1.08x TBV
Fair Value $89.10 10.9% downside ($89.10 - $100.04) / $100.04 = -10.9% ROTCE 11.9% → 1.73x TBV
Bull Case $115.83 15.8% upside ($115.83 - $100.04) / $100.04 = 15.8% ROTCE 13.7% → 2.12x TBV

Adjust Assumptions

11.9%
8.6%

Key Value Driver

ROTCE (11.9%) vs. cost of equity (8.6%)

Implied Market Multiple 2.24x

Plain-Language Summary

With ROTCE of 11.9% vs. 8.6% cost of equity, fair P/TBV is 1.73x on $44.69 tangible book, implying $89.10 per share. DDM cross-check: $47.37.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (33 analysts) $108.25
Analyst Range $103.00 – $111.00
Divergence from AlphaVal 18%

Warnings

⚠ Traditional cash flow models don't work well for banks — lending activity distorts how much cash the business actually generates.
⚠ Common valuation shortcuts don't apply here — for banks, interest payments are a core business cost, not overhead.
ℹ Dividend-based valuation: $47.37 (47% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.

Key Risks

  • Book value quality matters as much as level — check loan loss reserves
  • Interest rate sensitivity creates non-linear earnings surprises
  • Insurance reserving is actuarial, not financial — errors emerge slowly